Researchers find 'exercise pills'; Four companies drop $6M on lobbying;

> In recent years the Southeast U.S. has been recognized as a growing hub for biotech business. But many of the region's graduates are heading to other parts of the country to find jobs, and experts fear the "brain drain" could impact the future of the Southeast's biotech hopes. Report

> Four Big Pharma companies spent some serious cash to lobby congress in the second quarter of 2008. Report

> The FDA might be creating some faux direct-to-consumer commercials for a pretend blood pressure medication, which it plans to follow with an Internet survey of 2,400 adults to gauge the response of consumers aged 40 and older to the ads. Report

> A new study in the Archives of General Psychiatry seems to say incentives from managed care and more choices for psych drugs means psychiatrists increasingly turn to the prescription pad rather than the therapy couch. Report

> Two drugs known as Aicar and GW1516 have a dramatic ability to enhance the strength and fitness of animals, according to researchers at the Salk Institute in San Diego. Report

> A research team from Columbia and Harvard was able to reprogram stem cells taken from the skin of elderly patients into cells responsible for triggering amyotrophic lateral sclerosis, or ALS. Report

And Finally... Seven years and more than $50 billion after 9/11, biosecurity experts say the U.S. still has made only marginal progress developing the security measures and new therapeutics needed to protect the U.S. from the next bioterror threat. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.